Data gathered: August 1
AI Stock Analysis - Glaukos (GKOS)
Analysis generated August 1, 2025. Powered by Chat GPT.
Glaukos Corporation is a medical technology company focused on the development and commercialization of devices for the treatment of chronic eye diseases. The company's innovative solutions are primarily designed to address glaucoma, one of the leading causes of blindness worldwide. Glaukos has been a pioneer in the field of micro-invasive glaucoma surgery (MIGS) and continues to expand its product portfolio to offer comprehensive treatment options for ophthalmologists and patients.
Stock Alerts - Glaukos (GKOS)
 |
Glaukos | July 31 Price is down by -7.2% in the last 24h. |
|
Glaukos | May 1 Price is down by -16.4% in the last 24h. |
|
Glaukos | April 23 Price is up by 8.7% in the last 24h. |
|
Glaukos | April 16 Price is down by -7.5% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Glaukos
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 29 | Sign up | Sign up | Sign up |
| Sentiment | 80 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | 37 | Sign up | Sign up | Sign up |
| Patents | 61 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 180 | Sign up | Sign up | Sign up |
| Facebook Followers | 6,802 | Sign up | Sign up | Sign up |
| Instagram Followers | 3,513 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 854 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,631 | Sign up | Sign up | Sign up |
| Twitter Mentions | 12 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 89 | Sign up | Sign up | Sign up |
| Linkedin Employees | 961 | Sign up | Sign up | Sign up |
About Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
| Price | $86.16 |
| Target Price | Sign up |
| Volume | 1,510,000 |
| Market Cap | $5.37B |
| Year Range | $82.27 - $161.22 |
| Dividend Yield | 0% |
| Analyst Rating | 82% buy |
| Industry | Medical Devices |
In the news
 |
Glaukos price target lowered by $20 at Mizuho, here's whyJuly 31 - Thefly.com |
 |
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance RaisedJuly 31 - Yahoo |
 |
Glaukos Corporation 2025 Q2 - Results - Earnings Call PresentationJuly 30 - SeekingAlpha |
|
Glaukos Corporation (GKOS) Q2 2025 Earnings Call TranscriptJuly 30 - SeekingAlpha |
|
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue EstimatesJuly 30 - Yahoo |
|
Glaukos: Q2 Earnings SnapshotJuly 30 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 124M | 27M | 97M | -20M | -21M | -0.240 |
| Q1 '25 | 107M | 24M | 82M | -18M | -21M | -0.220 |
| Q4 '24 | 105M | 29M | 77M | -34M | -22M | -0.400 |
| Q3 '24 | 97M | 23M | 74M | -21M | -11M | -0.280 |
| Q2 '24 | 96M | 23M | 73M | -51M | -30M | -0.520 |
Insider Transactions View All
| Thurman Alex R. filed to sell 53,431 shares at $108.1. March 27 '25 |
| Thurman Alex R. filed to sell 53,462 shares at $107.4. March 27 '25 |
| Thurman Alex R. filed to sell 53,892 shares at $106.6. March 27 '25 |
| Foley Mark J filed to sell 54,249 shares at $120.7. February 28 '25 |
| Navratil Tomas filed to sell 72,437 shares at $147.1. February 19 '25 |
Similar companies
Read more about Glaukos (GKOS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Glaukos?
The Market Cap of Glaukos is $5.37B.
What is the current stock price of Glaukos?
Currently, the price of one share of Glaukos stock is $86.16.
How can I analyze the GKOS stock price chart for investment decisions?
The GKOS stock price chart above provides a comprehensive visual representation of Glaukos' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Glaukos shares. Our platform offers an up-to-date GKOS stock price chart, along with technical data analysis and alternative data insights.
Does GKOS offer dividends to its shareholders?
As of our latest update, Glaukos (GKOS) does not offer dividends to its shareholders. Investors interested in Glaukos should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Glaukos?
Some of the similar stocks of Glaukos are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.
.